On 22 May 2026, Australian Therapeutic Goods Administration (TGA) updated its guidance on complying with Unique Device Identification (UDI) timeframes for medical devices, outlining regulatory timelines for supplying UDI-compliant medical devices in Australia. The guidance is intended to help sponsors and manufacturers understand and meet Australia’s UDI obligations through clear explanations of compliance dates, phased implementation requirements and transitional arrangements. According to the TGA, the updated guidance provides practical examples to support stakeholders in understanding how the staged rollout of UDI requirements will apply to different categories of medical devices and in vitro diagnostic (IVD) devices. The phased approach is designed to allow industry participants to transition progressively while maintaining compliance with regulatory expectations and ensuring continuity of supply in the Australian market. The TGA clarified that this document specifically addresses compliance timelines and transitional arrangements and does not cover broader UDI requirements such as labelling, packaging or device identifiers. Sponsors and manufacturers are encouraged to review the related guidance on general UDI requirements for medical devices to better understand terminology, obligations and implementation expectations under Australia’s national UDI framework.
Consult
